2006
Cost-Effectiveness of Second-Generation Antipsychotics and Perphenazine in a Randomized Trial of Treatment for Chronic Schizophrenia
Rosenheck RA, Leslie DL, Sindelar J, Miller EA, Lin H, Stroup TS, McEvoy J, Davis SM, Keefe RS, Swartz M, Perkins DO, Hsiao JK, Lieberman J. Cost-Effectiveness of Second-Generation Antipsychotics and Perphenazine in a Randomized Trial of Treatment for Chronic Schizophrenia. American Journal Of Psychiatry 2006, 163: 2080-2089. PMID: 17151158, DOI: 10.1176/ajp.2006.163.12.2080.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAntipsychotic AgentsChronic DiseaseCost-Benefit AnalysisDrug CostsFollow-Up StudiesHealth Care CostsHumansLongitudinal StudiesMiddle AgedPatient DropoutsPerphenazinePsychiatric Status Rating ScalesQuality-Adjusted Life YearsResearch DesignSchizophreniaSchizophrenic PsychologyTreatment OutcomeEffectiveness of Switching Antipsychotic Medications
Essock SM, Covell NH, Davis SM, Stroup TS, Rosenheck RA, Lieberman JA. Effectiveness of Switching Antipsychotic Medications. American Journal Of Psychiatry 2006, 163: 2090-2095. PMID: 17151159, DOI: 10.1176/ajp.2006.163.12.2090.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAntipsychotic AgentsBenzodiazepinesCross-Over StudiesDibenzothiazepinesDose-Response Relationship, DrugDouble-Blind MethodDrug Administration ScheduleHumansMiddle AgedOlanzapinePatient DropoutsPsychotherapyQuetiapine FumarateResearch DesignRisperidoneSchizophreniaSchizophrenic PsychologySelection BiasSurvival AnalysisTreatment OutcomeConceptsMedication changesDifferent antipsychoticsCause treatment discontinuationCurrent medication regimensClinical Antipsychotic TrialsPhase 1 analysisPhase 1 findingsBaseline medicationsSwitching medicationsTreatment discontinuationMedication regimensPrimary outcomeMedication effectivenessAntipsychotic medicationAntipsychotic TrialsMedicationsAntipsychoticsClinical situationsOlanzapinePatientsRisperidoneIntervention effectivenessDearth of informationDiscontinuationRandom assignment
2002
Benefit‐Cost Analysis of Addiction Treatment: Methodological Guidelines and Empirical Application Using the DATCAP and ASI
French MT, Salomé HJ, Sindelar JL, McLellan AT. Benefit‐Cost Analysis of Addiction Treatment: Methodological Guidelines and Empirical Application Using the DATCAP and ASI. Health Services Research 2002, 37: 433-455. PMID: 12036002, PMCID: PMC1430361, DOI: 10.1111/1475-6773.031.Peer-Reviewed Original ResearchConceptsDrug Abuse Treatment Cost Analysis ProgramBenefit-cost analysisEconomic evaluationEconomic benefitsFuture economic researchTotal economic benefitTotal economic costFuture economic evaluationsEconomic researchDetailed methodological guidelinesEmpirical applicationConsecutive fiscal yearsSensitivity analysisOutpatient drug-free programsEconomic costsMethodological guidelinesFiscal yearCost dataSubsequent sensitivity analysisDrug-free programsResource useMethodological foundationsBenefitsCostEstimates
1991
Economic cost of illicit drug studies: critique and research agenda.
Sindelar JL. Economic cost of illicit drug studies: critique and research agenda. NIDA Research Monograph 1991, 113: 33-45. PMID: 1762641.Peer-Reviewed Original Research